Abstract:Background Pioglitazone is effective in nonalcoholic steatohepatitis (NASH), but the mechanisms of action are not completely understood. This study was designed to investigate the effects of pioglitazone on hepatic nuclear factor-kappa B (NF-kappa B) and cyclooxygenases-2 (COX-2) expression in NASH rats.Methods Thirty Sprague-Dawley male rats were randomly assigned to a control group (n=10), NASH group (n=10), and pioglitazone treatment group (n=10). Liver tissues were processed for histology by hematoxylin & eosin and Masson stained. Serum alanine aminotransferase (ALT), cholesterol, triglyceride, fasting blood glucose (FBG), fasting insulin (FINS) levels and biochemical parameters of antioxidant enzyme activities, tumor necrosis factor alpha (TNF-alpha), prostaglandin E-2 (PGE(2)) levels in serum and liver were measured. The mRNA and protein expression of peroxisome proliferator-activated receptor gamma (PPAR gamma), NF-kappa B and COX-2 were determined by real-time polymerase chain reaction, Western blotting and immunohistochemistry. One-way analysis of variance (ANOVA) and Wilcoxon's signed-rank test was used for the statistical analysis.Results There were severe steatosis, moderate inflammatory cellular infiltration and fibrosis in NASH rats. After pioglitazone treatment, steatosis, inflammation and fibrosis were significantly improved compared with the NASH group (chi(2)=20.40, P <0.001; chi(2)=20.17, P <0.001; chi(2)=13.98, P=0.002). Serum ALT, cholesterol, triglyceride, FBG, FINS levels were significantly elevated in the NASH group (P <0.05). In the NASH group, total anti-oxidation competence (T-AOC), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-PX) and malondialdehyde (MDA) levels in serum and liver were conspicuous disordered than those parameters in the control group. Meanwhile, TNF-alpha and PGE(2) levels in serum and liver were significantly increased compared with the control group. Immunohistochemistry showed NF-kappa B and COX-2 expression in liver was significantly elevated. However, PPAR gamma level was decreased in the NASH group. Real-time PCR and Western blotting revealed mRNA and protein expression of COX-2 were increased in the NASH group compared with the control group (0.57+/-0.08 vs. 2.83+/-0.24; 0.38+/-0.03 vs. 1.00+/-0.03, P <0.001 and P=0.004, respectively). After pioglitazone intervention, all of those parameters markedly improved (P <0.05 or P <0.01).Conclusion Down-regulating hepatic NF-kB and COX-2 expression, at least in part, is one of the possible therapeutic mechanisms of pioglitazone in NASH rats. Chin Med J 2012;125(13):2316-2321

PPARα/γ Agonists and Antagonists Differently Affect Hepatic Lipid Metabolism, Oxidative Stress and Inflammatory Cytokine Production in Steatohepatitic Rats

Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor α agonists

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.

Pioglitazone Ameliorates Nonalcoholic Steatohepatitis by Down-Regulating Hepatic Nuclear Factor-Kappa B and Cyclooxygenases-2 Expression in Rats.

The Pharmacodynamic And Differential Gene Expression Analysis Of Ppar Alpha/Delta Agonist Gft505 In Cdahfd-Induced Nash Model

The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model

The Effect of Rosiglitazone in Modulating Cyclooxygenases-2 in Nonalcoholic Steatohepatitis Rats

Intestinal peroxisome proliferator-activated receptor -fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis

The Effects of New Selective PPARα Agonist CP775146 on Systematic Lipid Metabolism in Obese Mice and Its Potential Mechanism.

Regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease

Regulation of the Macrophage-Hepatic Stellate Cell Interaction by Targeting Macrophage Peroxisome Proliferator-Activated Receptor Gamma to Prevent Non-Alcoholic Steatohepatitis Progression in Mice

PPARα/γ Antagonists Reverse the Ameliorative Effects of Osthole on Hepatic Lipid Metabolism and Inflammatory Response in Steatohepatitic Rats

Regulation of Peroxisome Proliferator-Activated Receptor-Gamma Activity Affects the Hepatic Stellate Cell Activation and the Progression of NASH Via TGF-β1/Smad Signaling Pathway

Anti-steatotic effects of PPAR-alpha and gamma involve gut-liver axis modulation in high-fat diet-fed mice

Overexpression of Peroxisome Proliferator-Activated Receptor Gamma in Liver of Rats with Non-Alcoholic Fatty Liver Disease Chronically Fed with High-Fat Diet

Regulation of Adipokines by Polyunsaturated Fatty Acids in a Rat Model of Non-Alcoholic Steatohepatitis.

The lack of PPARα exacerbated the progression of non-alcoholic steatohepatitis in mice with spleen deficiency syndrome by triggering an inflammatory response

Regulation of the macrophage‐hepatic stellate cell interaction by targeting macrophage PPARγ to prevent NASH progression in mice

Treatment With Ppar Delta Agonist Alleviates Non-Alcoholic Fatty Liver Disease By Modulating Glucose And Fatty Acid Metabolic Enzymes In A Rat Model

Advances of peroxisome proliferator-activated receptors agonists in the treatment of non-alcoholic steatohepatitis